心血管、神经及免疫不良事件与23价肺炎球菌多糖疫苗
该研究利用韩国免疫登记信息系统与国民健康信息数据库(2018至2021年)链接数据库,采用自我对照风险区间设计,纳入65岁及以上有PPSV23接种史且发生目标事件的1802739例接种者中的4355例。风险区间为接种后1至28天,对照区间为57至112天,采用条件泊松回归估计发生率比(IRR)。结果显示心肌梗死、心力衰竭、卒中、贝尔麻痹、吉兰-巴雷综合征、脓毒症及血小板减少症的风险均未显著升高。作者认为PPSV23更新后的安全性特征为制定老年人免疫策略提供了支持性证据。
要点
- 在65岁及以上PPSV23接种者中,心肌梗死风险未见显著升高(IRR 0.96;95%CI 0.81-1.15)。
- 心力衰竭(IRR 0.85;95%CI 0.70-1.04)与卒中(IRR 0.92;95%CI 0.84-1.02)风险亦未见显著升高。
- 贝尔麻痹(IRR 0.95;95%CI 0.72-1.26)与吉兰-巴雷综合征(IRR 0.27;95%CI 0.06-1.17)风险未显著升高。
- 脓毒症(IRR 0.99;95%CI 0.74-1.32)与血小板减少症(IRR 1.18;95%CI 0.60-2.35)风险未显著升高。
- 作者认为PPSV23更新后的安全性特征为制定老年人免疫策略提供了支持性证据。
适用人群与场景
- 65岁及以上、有PPSV23接种史且于风险区间或对照区间内发生目标心血管、神经或免疫事件的韩国人群(数据来源为韩国免疫登记信息系统与国民健康信息数据库链接数据库,2018至2021年)。
诊断标准与关键阈值
- 风险区间定义为PPSV23接种后1至28天,对照区间定义为接种后57至112天。
- 目标结局包括6项心血管事件(心肌梗死、心房颤动、心肌病、心力衰竭、低血压、心肌炎或心包炎)、2项神经事件(贝尔麻痹、吉兰-巴雷综合征)和3项免疫事件(脓毒症、血小板减少症、过敏反应)。
研究设计与关键结果
- 研究类型为基于人群的队列研究,采用自我对照风险区间设计,数据来自韩国免疫登记信息系统与国民健康信息数据库链接数据库(2018至2021年),数据分析时间为2022年11月至2023年4月。
- 在1802739例接种PPSV23疫苗且发生至少1项目标事件者中,共纳入4355例(平均[SD]年龄72.4[8.2]岁;男性2272例[52.1%])。
- 心血管事件:心肌梗死IRR 0.96(95%CI 0.81-1.15)、心力衰竭IRR 0.85(95%CI 0.70-1.04)、卒中IRR 0.92(95%CI 0.84-1.02),均无显著关联。
- 神经与免疫结局:贝尔麻痹IRR 0.95(95%CI 0.72-1.26)、吉兰-巴雷综合征IRR 0.27(95%CI 0.06-1.17)、脓毒症IRR 0.99(95%CI 0.74-1.32)、血小板减少症IRR 1.18(95%CI 0.60-2.35),均未见风险升高。
证据类型、等级与局限
- 证据类型:基于人群的自我对照风险区间队列研究。
- 作者结论:PPSV23接种后大多数心血管、神经或免疫不良事件风险未见明显升高,更新后的安全性特征为制定老年人免疫策略提供了支持性证据。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于65岁及以上老年人,本文结果提示PPSV23接种后大多数心血管、神经及免疫不良事件风险未见明显升高,作者认为该安全性特征为制定老年人免疫策略提供了支持性证据。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Despite widespread immunization with the 23-valent pneumococcal polysaccharide vaccine (PPSV23), safety concerns remain owing to a lack of statistical power and largely outdated evidence.
OBJECTIVE: To evaluate the association between cardiovascular, neurological, and immunological adverse events and PPSV23 vaccination in older adults.
DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study using a self-controlled risk interval design used a large linked database created by linking the Korea Immunization Registry Information System and the National Health Information Database (2018 to 2021). Participants included patients aged 65 years or older with a history of PPSV23 vaccination and incident cardiovascular, neurological, or immunological events during the risk and control intervals. Data were analyzed from November 2022 to April 2023.
EXPOSURE: 23-valent pneumococcal polysaccharide vaccine.
MAIN OUTCOMES AND MEASURES: The occurrence of 1 among 6 cardiovascular events (myocardial infarction, atrial fibrillation, cardiomyopathy, heart failure, hypotension, and myocarditis or pericarditis), 2 neurological events (Bell palsy and Guillain-Barré syndrome), and 3 immunological events (sepsis, thrombocytopenia, and anaphylaxis) during the risk and control periods. The risk and control intervals were defined as 1 to 28 and 57 to 112 days after PPSV23 vaccination, respectively. Conditional Poisson regression was used to estimate the incidence rate ratio (IRR) with a 95% CI.
RESULTS: Altogether, 4355 of the 1 802 739 individuals who received PPSV23 vaccination and experienced at least 1 outcome event were included (mean [SD] age, 72.4 [8.2] years; 2272 male participants [52.1%]). For cardiovascular events, there were no significant associations for myocardial infarction (IRR, 0.96; 95% CI, 0.81-1.15), heart failure (IRR, 0.85; 95% CI, 0.70-1.04), and stroke (IRR, 0.92; 95% CI, 0.84-1.02). Similarly, no increased risks were observed for neurological and immunological outcomes: Bell palsy (IRR, 0.95; 95% CI, 0.72-1.26), Guillain-Barré syndrome (IRR, 0.27; 95% CI, 0.06-1.17), sepsis (IRR, 0.99; 95% CI, 0.74-1.32), and thrombocytopenia (IRR, 1.18; 95% CI, 0.60-2.35).
CONCLUSIONS AND RELEVANCE: In this self-controlled risk interval study, there was no appreciable increase in risk for most cardiovascular, neurological, or immunological adverse events following PPSV23. The updated safety profile of PPSV23 provides supportive evidence for the establishment of immunization strategies for older adults.
参考来源
- Yoon D, Jeon HL, Kim JH, et al. Cardiovascular, Neurological, and Immunological Adverse Events and the 23-Valent Pneumococcal Polysaccharide Vaccine. JAMA Netw Open. 2024. PMID: 38252436. doi:10.1001/jamanetworkopen.2023.52597
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。